Alcohol septal ablation was introduced as a new treatment option for symptomatic patients with hypertrophic obstructive cardiomyopathy (HOCM) about 2 decades ago, but there has been persistent concern that the alcohol-induced infarction might have adverse long-term effects and increase the risk of cardiac mortality. Batzner et al studied the long-term survival after echo-guided alcohol septal ablation (percutaneous transluminal septal myocardial ablation [PTSMA]) in symptomatic patients with HOCM.